Inhibrx Biosciences, INC Schedule 13G passive stakes
Filed when an investor crosses five percent without intending to seek control — the passive counterpart to a 13D.
NASDAQ
Bank of America Corporation has reported beneficial ownership of 5.9% of Inhibrx Biosciences, Inc. common stock as of June 30, 2026.
NASDAQ
Viking Global Investors filed an amended Schedule 13G to reflect the retirement of David C. Ott from its reporting group.
NASDAQ
Perceptive Advisors, Joseph Edelman, and Perceptive Life Sciences Master Fund have filed a Schedule 13G reporting a 9.99% beneficial ownership stake in Inhibrx Biosciences, Inc.
NASDAQ
Morgan Stanley and its subsidiary, Morgan Stanley Capital Services LLC, have disclosed beneficial ownership of 7.9% of Inhibrx Biosciences, Inc.'s common stock.
NASDAQ
SCHEDULE 13G: BlackRock Discloses 5.3% Stake in INHIBRX BIOSCIENCES
BlackRock, Inc. has filed a Schedule 13G, reporting a 5.3% beneficial ownership stake in INHIBRX BIOSCIENCES, INC. as of December 31, 2025.
NASDAQ
BlackRock, Inc. has reported a reduced beneficial ownership in Inhibrx Biosciences, Inc. to 4.7% of common stock.
NASDAQ
BlackRock, Inc. has reported a passive beneficial ownership of 5.7% of Inhibrx Biosciences, Inc.'s common stock as of December 31, 2024.